The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease

Gianfranco Spalletta, Robert G. Robinson, Luca Cravello, Francesco E. Pontieri, Mariangela Pierantozzi, Alessandro Stefani, Jeffrey D. Long, Carlo Caltagirone, Francesca Assogna

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Neuropsychiatric and cognitive symptoms are common in patients with Parkinson's disease (PD) from the early stage of the disease but their course is still unclear. In this study we investigated prospectively the progression of affective and cognitive symptoms and disorders in de novo idiopathic PD patients. Twenty-four de novo drug naïve PD patients underwent a comprehensive neurological, psychopathological and neuropsychological evaluation at the first diagnostic visit (OFF), after 4-6 months when the antiparkinsonian therapy regimen was stabilized (ON-1), and at one year following the ON-1 follow-up visit (ON-2). Generalized least squares analysis revealed a significant improvement over time in the depressive mood, short and long term episodic verbal memory, visual memory, and the motor symptoms. Pairwise comparisons showed a significant change from OFF to ON-1 for all the aforementioned variables, except for short term episodic verbal memory which approached significance. A significant improvement from ON-1 to ON-2, however, was shown for short term episodic verbal memory. An ancillary analysis indicated that overall level and change in a number of cognitive variables, but not depression, was conditional upon age of onset, education, and sometime gender. In conclusion, early stage PD is not associated with affective and cognitive deterioration. On the contrary, very specific neuropsychiatric and cognitive symptoms may improve. This study provides Class III evidence that antiparkinsonian treatment commonly used in the clinical practice improves memory performance and depression severity in de novo patients with PD.

Original languageEnglish
Pages (from-to)1126-1132
Number of pages7
JournalJournal of Neurology
Volume261
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Neurobehavioral Manifestations
Affective Symptoms
Parkinson Disease
Episodic Memory
Antiparkinson Agents
Short-Term Memory
Depression
Long-Term Memory
Least-Squares Analysis
Mood Disorders
Age of Onset
Education
Therapeutics
Pharmaceutical Preparations

Keywords

  • Depression
  • Memory
  • Neuropsychology
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease. / Spalletta, Gianfranco; Robinson, Robert G.; Cravello, Luca; Pontieri, Francesco E.; Pierantozzi, Mariangela; Stefani, Alessandro; Long, Jeffrey D.; Caltagirone, Carlo; Assogna, Francesca.

In: Journal of Neurology, Vol. 261, No. 6, 2014, p. 1126-1132.

Research output: Contribution to journalArticle

Spalletta, Gianfranco ; Robinson, Robert G. ; Cravello, Luca ; Pontieri, Francesco E. ; Pierantozzi, Mariangela ; Stefani, Alessandro ; Long, Jeffrey D. ; Caltagirone, Carlo ; Assogna, Francesca. / The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease. In: Journal of Neurology. 2014 ; Vol. 261, No. 6. pp. 1126-1132.
@article{27df77da60794cc1b49250b5af95a2a2,
title = "The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease",
abstract = "Neuropsychiatric and cognitive symptoms are common in patients with Parkinson's disease (PD) from the early stage of the disease but their course is still unclear. In this study we investigated prospectively the progression of affective and cognitive symptoms and disorders in de novo idiopathic PD patients. Twenty-four de novo drug na{\"i}ve PD patients underwent a comprehensive neurological, psychopathological and neuropsychological evaluation at the first diagnostic visit (OFF), after 4-6 months when the antiparkinsonian therapy regimen was stabilized (ON-1), and at one year following the ON-1 follow-up visit (ON-2). Generalized least squares analysis revealed a significant improvement over time in the depressive mood, short and long term episodic verbal memory, visual memory, and the motor symptoms. Pairwise comparisons showed a significant change from OFF to ON-1 for all the aforementioned variables, except for short term episodic verbal memory which approached significance. A significant improvement from ON-1 to ON-2, however, was shown for short term episodic verbal memory. An ancillary analysis indicated that overall level and change in a number of cognitive variables, but not depression, was conditional upon age of onset, education, and sometime gender. In conclusion, early stage PD is not associated with affective and cognitive deterioration. On the contrary, very specific neuropsychiatric and cognitive symptoms may improve. This study provides Class III evidence that antiparkinsonian treatment commonly used in the clinical practice improves memory performance and depression severity in de novo patients with PD.",
keywords = "Depression, Memory, Neuropsychology, Parkinson's disease",
author = "Gianfranco Spalletta and Robinson, {Robert G.} and Luca Cravello and Pontieri, {Francesco E.} and Mariangela Pierantozzi and Alessandro Stefani and Long, {Jeffrey D.} and Carlo Caltagirone and Francesca Assogna",
year = "2014",
doi = "10.1007/s00415-014-7327-6",
language = "English",
volume = "261",
pages = "1126--1132",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "6",

}

TY - JOUR

T1 - The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease

AU - Spalletta, Gianfranco

AU - Robinson, Robert G.

AU - Cravello, Luca

AU - Pontieri, Francesco E.

AU - Pierantozzi, Mariangela

AU - Stefani, Alessandro

AU - Long, Jeffrey D.

AU - Caltagirone, Carlo

AU - Assogna, Francesca

PY - 2014

Y1 - 2014

N2 - Neuropsychiatric and cognitive symptoms are common in patients with Parkinson's disease (PD) from the early stage of the disease but their course is still unclear. In this study we investigated prospectively the progression of affective and cognitive symptoms and disorders in de novo idiopathic PD patients. Twenty-four de novo drug naïve PD patients underwent a comprehensive neurological, psychopathological and neuropsychological evaluation at the first diagnostic visit (OFF), after 4-6 months when the antiparkinsonian therapy regimen was stabilized (ON-1), and at one year following the ON-1 follow-up visit (ON-2). Generalized least squares analysis revealed a significant improvement over time in the depressive mood, short and long term episodic verbal memory, visual memory, and the motor symptoms. Pairwise comparisons showed a significant change from OFF to ON-1 for all the aforementioned variables, except for short term episodic verbal memory which approached significance. A significant improvement from ON-1 to ON-2, however, was shown for short term episodic verbal memory. An ancillary analysis indicated that overall level and change in a number of cognitive variables, but not depression, was conditional upon age of onset, education, and sometime gender. In conclusion, early stage PD is not associated with affective and cognitive deterioration. On the contrary, very specific neuropsychiatric and cognitive symptoms may improve. This study provides Class III evidence that antiparkinsonian treatment commonly used in the clinical practice improves memory performance and depression severity in de novo patients with PD.

AB - Neuropsychiatric and cognitive symptoms are common in patients with Parkinson's disease (PD) from the early stage of the disease but their course is still unclear. In this study we investigated prospectively the progression of affective and cognitive symptoms and disorders in de novo idiopathic PD patients. Twenty-four de novo drug naïve PD patients underwent a comprehensive neurological, psychopathological and neuropsychological evaluation at the first diagnostic visit (OFF), after 4-6 months when the antiparkinsonian therapy regimen was stabilized (ON-1), and at one year following the ON-1 follow-up visit (ON-2). Generalized least squares analysis revealed a significant improvement over time in the depressive mood, short and long term episodic verbal memory, visual memory, and the motor symptoms. Pairwise comparisons showed a significant change from OFF to ON-1 for all the aforementioned variables, except for short term episodic verbal memory which approached significance. A significant improvement from ON-1 to ON-2, however, was shown for short term episodic verbal memory. An ancillary analysis indicated that overall level and change in a number of cognitive variables, but not depression, was conditional upon age of onset, education, and sometime gender. In conclusion, early stage PD is not associated with affective and cognitive deterioration. On the contrary, very specific neuropsychiatric and cognitive symptoms may improve. This study provides Class III evidence that antiparkinsonian treatment commonly used in the clinical practice improves memory performance and depression severity in de novo patients with PD.

KW - Depression

KW - Memory

KW - Neuropsychology

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84903649211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903649211&partnerID=8YFLogxK

U2 - 10.1007/s00415-014-7327-6

DO - 10.1007/s00415-014-7327-6

M3 - Article

VL - 261

SP - 1126

EP - 1132

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 6

ER -